ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free Bevacizumab (Avastin®) in serum and plasma.<br><br>
The drug Bevacizumab (trade name Avastin®)is a recombinant human IgG1:ƙ monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms and it has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.<br><br>
Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial. For research use only, not for use in diagnostic procedures.
- Assay Description:
- 1 hour incubation (RT) + 30 min. (RT) + 15 min. (RT) = 1 hour, 45 min. total incubation time
- Catalog number:
- TM09010
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Enzyme immunoassay (ELISA) technique.
- FDA Status:
- For research use only, not for use in diagnostic procedures.
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- standards:
- 5 standards, ready to use
- Standard range:
- 0 / 6 - 200 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 2 ng/mL
- Species:
- Human
- Products related:
- Anti-Bevacizumab (Avastin®) ELISA
Bevacizumab (Avastin®) (mAb-based) ELISA - Additional info:
